Lupin gets approval for Rufinamide Oral Suspension

21 Dec 2020 Evaluate

Lupin has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration, to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.

Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1631.60 -80.45 (-4.70%)
23-May-2024 15:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1494.95
Dr. Reddys Lab 5882.45
Cipla 1487.45
Zydus Lifesciences 1087.65
Lupin 1631.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.